NKTR
Delayed Nasdaq - 06/22 10:00:00 pm
52.85USD
-5.39%
| Prev. | 55.8600 |
| Open | 56.1000 |
| High | 56.1950 |
| Low | 52.8400 |
| Volume | 21 720 134 |
Financials
|
|
Company
Nektar Therapeutics is a clinical-stage biopharmaceutical company, which engages in developing drug candidates that utilize its PEGylation and polymer conjugate technology platforms.It operates through the United States and Europe geogrpahical segments.The company was founded in 1990 and is...
| Sector : |
Biotechnology & Medical Research - NEC
|
| Calendar : |
2018-06-26 Shareholder meeting
|
| Trading Rating : |
| Investor Rating : |
Latest news
| 06/22 | NEKTAR THERAPEUTICS : U.S. Patents Awarded to Inventors in Alabama (June 22) | AQ |
| 06/21 | NEKTAR THERAPEUTICS : New Data for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Low Back Pain in Adult Patients New to Opioid Therapy, Presented at... | AQ |
| 06/14 | NEKTAR THERAPEUTICS : New Data for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Low Back Pain in Adult Patients New to Opioid Therapy, Presented at College on Problems of Drug Dependence 80th Annual Scientific Meeting | PR |
| 06/08 | FRIDAY 6/8 INSIDER BUYING REPORT : Yumc, nktr | AQ |
| 06/07 | SYNDAX PHARMACEUTICALS : and Nektar Therapeutics Announce Immuno-Oncology Clinical Trial Collaboration | AQ |
| 06/07 | NEKTAR THERAPEUTICS : Entry into a Material Definitive Agreement (form 8-K) | AQ |
| 06/06 | NEKTAR THERAPEUTICS : Bristol-Myers Squibb - Preliminary Data for NKTR-214 in Combination with Opdivo for Patients with Stage IV Metastatic Melanoma | AQ |
| 06/05 | NEKTAR THERAPEUTICS : to Webcast Presentation at the Jefferies 2018 Healthcare Conference in New York | PR |
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
| Trend | Bearish | Bearish | Bullish |
| Resistance | 69,4 | 77,2 | 108 |
| Spread/Res. | -24% | -32% | -51% |
| Spread/Supp. | 0,53% | 0,53% | 23% |
| Support | 52,6 | 52,6 | 43,0 |
